Typharm

Typharm

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Typharm Group is a long-established, privately-held UK pharmaceutical company with a diversified business model encompassing generic drug manufacturing, contract packaging, and community pharmacy operations. With over 40 years of experience under its current family ownership, the company focuses on delivering cost-effective, essential medicines in areas like dermatology, wound care, and digestive health. Led by Managing Director and practicing pharmacist Chandra Ondhia, Typharm leverages its MHRA-accredited manufacturing and packaging facilities to serve both domestic and international markets. The company's strategy is built on a foundation of operational integrity, patient safety, and partnerships within the healthcare ecosystem.

DermatologyWound CareDigestive HealthPain and FeverRespiratory HealthProstate Cancer

Technology Platform

Integrated pharmaceutical manufacturing, formulation, and MHRA-accredited contract packaging infrastructure for generic and OTC medicines.

Opportunities

Growth in the generic drug market driven by healthcare cost containment and patent expiries presents a stable demand base.
The contract packaging (Packpharm) business can capitalize on the pharmaceutical industry's trend towards outsourcing non-core manufacturing operations.
Further geographic expansion of exports beyond the UK and EU offers a clear path for revenue growth.

Risk Factors

Intense price competition in the generic pharmaceuticals sector could pressure profit margins.
The company faces significant regulatory risk, as manufacturing compliance issues with the MHRA or other health authorities could disrupt operations.
Its concentration on the UK market and mature product portfolio may limit high-growth potential compared to innovative biotech firms.

Competitive Landscape

Typharm competes in the crowded generic pharmaceutical market against large multinational generics firms (e.g., Teva, Sandoz, Viatris) and other UK-focused generic manufacturers. In contract packaging, it competes with specialized CDMOs (Contract Development and Manufacturing Organizations). Its community pharmacy chain operates in a competitive UK retail pharmacy sector dominated by large chains like Boots and independent pharmacies.